“Shift Towards Generic Versions”
As the patents for branded Canagliflozin expire, the emergence of generic versions is reshaping the market. Generic versions offer a more affordable alternative to the original branded drug, making it accessible to a broader patient base, especially in emerging markets where affordability is a critical factor. This trend reflects a broader move toward cost-effective treatment options in both developed and developing regions. The availability of generics allows healthcare systems to manage growing patient populations with diabetes and chronic kidney disease more sustainably, while also fostering competition and increasing the volume of sales in the market.
